美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

290.35

+11.194.01%

盤後：290.350.00000.00%18:58 EDT

成交量：80.49萬

成交額：2.34億

市值：343.92億

市盈率：-78.40

高：298.00

開：297.00

低：287.33

收：279.16

資料載入中...

總覽公司新聞公告

30天通關！NMPA再掀審批革命

7月14日百濟神州-UAH溢價達62.22%，位居AH股溢價率第70位

2025年醫保政策與產業動態：產業佈局升級與行業監管強化

東風已至！創新藥，將迎歷史性拐點？

百濟神州暗藏殺招

百奧賽圖與百濟神州深化合作達成抗體分子全球許可協議

百濟神州7月10日成交額為5230.17萬美元

CXO板塊也爆了！藥明康德上半年淨利潤預計翻倍，漲超9%

這款國產 PD-1 在海外又有新消息

Insight数据库

醫保目錄調整進展；百濟神州達成一協議｜21健訊Daily

21世纪经济报道

百濟神州：歐盟委員會批准百澤安聯合化療用於鼻咽癌患者一線治療

南方财经网

7月10日百濟神州宣佈歐盟委員會（EC）已批准百澤安（替雷利珠單抗）聯合吉西他濱和順鉑用於不適合根治性手術或放療的轉移或

百濟神州7月9日成交額為9172.04萬美元

港股早評：三大指數低開科技股多數下跌寧德時代開漲2.6%再創新高

百奧賽圖與百濟神州達成抗體分子許可協議，加速創新藥物開發

美国商业资讯

百濟神州美股漲逾3%

每日经济新闻

百濟神州美股漲逾3%一季度中國創新藥海外授權總額再創新高。

【美股異動 | 百濟神州(ONC.US)漲逾3% 一季度中國創新藥海外授權總額再創新高】智通財經APP獲悉，週三，百濟神

美股異動 | 百濟神州(ONC.US)漲逾3% 一季度中國創新藥海外授權總額再創新高

百濟神州7月8日成交額為6492.56萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":290.35,"timestamp":1752782400000,"preClose":279.16,"halted":0,"volume":804925,"hourTrading":{"tag":"盘后","latestPrice":290.35,"preClose":290.35,"latestTime":"18:58 EDT","volume":2517,"amount":730606.265,"timestamp":1752793098926},"delay":0,"floatShares":75541600,"shares":118450658,"eps":-3.70325,"marketStatus":"已收盤","change":11.19,"latestTime":"07-17 16:00:00 EDT","open":297,"high":298,"low":287.33,"amount":234286477.13349998,"amplitude":0.038222,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1752825600000},"marketStatusCode":5,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":279.16,"preHourTrading":{"tag":"盘前","latestPrice":295.6,"preClose":279.16,"latestTime":"09:28 EDT","volume":6738,"amount":2005797.0155399998,"timestamp":1752758886062},"postHourTrading":{"tag":"盘后","latestPrice":290.35,"preClose":290.35,"latestTime":"18:58 EDT","volume":2517,"amount":730606.265,"timestamp":1752793098926},"volumeRatio":2.1777,"impliedVol":0.4681,"impliedVolPercentile":0.7836},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":2.1777,"shares":118450658,"dividePrice":0,"high":298,"amplitude":0.038222,"preClose":279.16,"low":287.33,"week52Low":148.81,"pbRate":"9.83","psRate":"8.24","week52High":298,"institutionHeld":0,"latestPrice":290.35,"eps":-3.70325,"divideRate":0,"volume":804925,"delay":0,"ttmEps":-3.70325,"open":297,"prevYearClose":184.71,"prevWeekClose":250.3,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":253.39,"twentyDayClose":254.09,"sixtyDayClose":229.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551134532","title":"30天通關！NMPA再掀審批革命","url":"https://stock-news.laohu8.com/highlight/detail?id=2551134532","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551134532?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 09:03","pubTimestamp":1752541434,"startTime":"0","endTime":"0","summary":"近期，NMPA发布《优化创新药临床试验审评审批有关事项》，提出将创新药临床试验默示许可的审评时限由60日压缩至30日。与NMPA推进的“临床快审批”形成合力，中国创新药正在迎来“研发—审批—支付”三位一体政策闭环的新格局。于中国药企而言，30日通道的设立无疑是一次重大制度红利。在美国，FDA自1997年起即实行IND 30天审评制，强调申报资料完整性、临床试验设计合理性及申办方资质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715090641a6a9c704&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715090641a6a9c704&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK0239","06160","688235"],"gpt_icon":0},{"id":"2551909815","title":"7月14日百濟神州-UAH溢價達62.22%，位居AH股溢價率第70位","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909815","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909815?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 16:43","pubTimestamp":1752482632,"startTime":"0","endTime":"0","summary":"7月14日，上证指数涨0.27%，收报3519.65点，恒生指数涨0.26%，收报24203.32点。当日收盘，百济神州-UA股报225.94元，跌幅1.72%，H股报152.5港元，下跌1.04%。资料显示，百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526","06160"],"gpt_icon":0},{"id":"2551130912","title":"2025年醫保政策與產業動態：產業佈局升級與行業監管強化","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130912","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551130912?lang=zh_tw&edition=fundamental","pubTime":"2025-07-13 08:05","pubTimestamp":1752365100,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，随着国家医疗保障体系的不断完善，2025年医保相关政策及医药产业发展呈现显著变化。国家医保局、药监局等机构通过政策引导与严格监管，进一步优化药品供给结构，并强化了对违法违规行为的打击力度。数据显示，2025年目录调整将直接影响超万种药品的市场准入资格。总结2025年医保政策与产业布局呈现多维度深化态势：目录动态调整优化资源配置、监管强化保障行业规范、资本助力推动技术创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","02315","ONC","BK0239","06160"],"gpt_icon":0},{"id":"2550991907","title":"東風已至！創新藥，將迎歷史性拐點？","url":"https://stock-news.laohu8.com/highlight/detail?id=2550991907","media":"浩海投研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550991907?lang=zh_tw&edition=fundamental","pubTime":"2025-07-12 14:03","pubTimestamp":1752300180,"startTime":"0","endTime":"0","summary":"像百济神州2024年总营收同比大增56.2%至272亿元，亏损也收窄到49.78亿元，多家券商预计2025年百济神州会迎来利润转正的历史性拐点。长期来看，中国仍将是全球创新药市场的主要引擎。根据行业预测，2030年中国创新药整体销售额将突","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712150044a4462ca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712150044a4462ca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","LU2488822045.USD","688336","600276","00013","06978","BK1583","01276","BK1574","ONC","01801","01530","688331","BK1589","LEGN","LU1969619763.USD","06160","HCM","09926","09995","688235","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2550673969","title":"百濟神州暗藏殺招","url":"https://stock-news.laohu8.com/highlight/detail?id=2550673969","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550673969?lang=zh_tw&edition=fundamental","pubTime":"2025-07-12 07:31","pubTimestamp":1752276667,"startTime":"0","endTime":"0","summary":"而另一边，“创新药一哥”百济神州已经明确表示即将“上岸”：预计将实现2025年全年GAAP经营利润为正，经营活动产生正现金流。然而，当行业目光聚焦于血液瘤产品的锋芒时，百济神州的实体瘤管线却如深海暗流般积蓄能量，爆发在即。01全面出击实体瘤领域也是百济神州的主要引擎之一。2024年，百济交出了一份令市场满意的业绩答卷。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712073404a445a3ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712073404a445a3ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK0239","ONC"],"gpt_icon":0},{"id":"2550986727","title":"百奧賽圖與百濟神州深化合作 達成抗體分子全球許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2550986727","media":"DoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550986727?lang=zh_tw&edition=fundamental","pubTime":"2025-07-11 14:57","pubTimestamp":1752217023,"startTime":"0","endTime":"0","summary":"百奥赛图近日宣布，与百济神州就抗体分子达成全球许可协议。此次合作是在百济神州已获百奥赛图RenMice®全人抗体平台授权的基础上，进一步拓展至具体抗体分子领域的授权许可，体现了双方在抗体研发方向上的持续协同与深入布局。此次协议的签署不仅强化了双方在创新生物药领域的合作关系，也显示出百奥赛图技术平台在全球新药开发中的重要价值。通过资源共享与优势互补，双方有望加速推进抗体药物的全球化开发进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071114591297a1f1a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071114591297a1f1a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","688235","ONC"],"gpt_icon":0},{"id":"2550607433","title":"百濟神州7月10日成交額為5230.17萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550607433","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550607433?lang=zh_tw&edition=fundamental","pubTime":"2025-07-11 12:39","pubTimestamp":1752208793,"startTime":"0","endTime":"0","summary":"美东时间2025年7月10日，百济神州成交额为5230.17万美元，成交额较昨日减少42.98%，当日成交量为20.68万股。百济神州于2025年7月10日跌0.9%，报253.39美元，该股过去5个交易日涨3.71%，年初至今涨37.18%，过去60日涨10.0%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711123957a443ef51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711123957a443ef51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2550605731","title":"CXO板塊也爆了！藥明康德上半年淨利潤預計翻倍，漲超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550605731","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550605731?lang=zh_tw&edition=fundamental","pubTime":"2025-07-11 10:03","pubTimestamp":1752199403,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["CXO.AU","LU2380233275.USD","06160","159760","LU1920062954.HKD","ONC","02269","688271","159982","161027","09939","399441","LU0471298777.SGD","SG9999002562.SGD","LU2041044095.USD","LU1794554557.SGD","LU1688375341.USD","01877","LU2401740654.USD","603259","BK7095","LU0052750758.USD","688180","SW","LU0327786744.USD","LU0417516902.SGD","LU1046422090.SGD","LU1997245094.SGD","LU0181495838.USD","159929","159992","512010","688114","161726","159892","159938","LU1242518931.SGD","LU0471298694.HKD","06978","02268","588130","688235","LU0823426480.USD","LU1997245177.USD","CXO","BK1576","02359","159891"],"gpt_icon":0},{"id":"2550677795","title":"這款國產 PD-1 在海外又有新消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2550677795","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550677795?lang=zh_tw&edition=fundamental","pubTime":"2025-07-11 08:18","pubTimestamp":1752193081,"startTime":"0","endTime":"0","summary":"替雷利珠单抗联合化疗组中位 PFS 为 9.2 个月，而安慰剂联合化疗组为 7.4 个月。额外 12 个月随访更新分析显示，有效性结果与期中分析结果一致。替雷利珠单抗联合化疗总体耐受性良好，未发现新的安全性信号。替雷利珠单抗是百济神州自主研发的 PD-1 抑制剂，2019 年 12 月在国内获批，2023 年 9 月，替雷利珠单抗获得欧盟批准，用于治疗特定类型的食管鳞状细胞癌，成为 PD-1 领域首款“出海”产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083536a6a27bde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083536a6a27bde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","06160","688235","ONC"],"gpt_icon":0},{"id":"2550672907","title":"醫保目錄調整進展；百濟神州達成一協議｜21健訊Daily","url":"https://stock-news.laohu8.com/highlight/detail?id=2550672907","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550672907?lang=zh_tw&edition=fundamental","pubTime":"2025-07-11 07:47","pubTimestamp":1752191224,"startTime":"0","endTime":"0","summary":"政策动向“两保”目录调整方案发布7月10日，国家医保局正式发布《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507113453905588.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507113453905588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","06160","BK1161","BK4139","LU1969619763.USD","BK1588","LU2328871848.SGD","BK1500","ONC","LU0588546209.SGD","BK1583","BK4526"],"gpt_icon":0},{"id":"2550641478","title":"百濟神州：歐盟委員會批准百澤安聯合化療用於鼻咽癌患者一線治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2550641478","media":"南方财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550641478?lang=zh_tw&edition=fundamental","pubTime":"2025-07-10 18:39","pubTimestamp":1752143991,"startTime":"0","endTime":"0","summary":"7月10日，百济神州宣布，欧盟委员会（EC）已批准百泽安?（替雷利珠单抗）联合吉西他滨和顺铂用于不适合根治性手术或放疗的转移或复发性鼻咽癌（NPC）成年患者的一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507103453490572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","BK4139","LU0588546209.SGD","BK1583","BK1588","BK4526","LU0307460666.USD","BK1161","ONC","BK1500","LU2328871848.SGD","06160"],"gpt_icon":0},{"id":"2550649333","title":"7月10日百濟神州宣佈歐盟委員會（EC）已批准百澤安（替雷利珠單抗）聯合吉西他濱和順鉑用於不適合根治性手術或放療的轉移或","url":"https://stock-news.laohu8.com/highlight/detail?id=2550649333","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550649333?lang=zh_tw&edition=fundamental","pubTime":"2025-07-10 18:18","pubTimestamp":1752142682,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["688235","LU0307460666.USD","06160","BK1583","BK4201","BK4139","BK0239","EC","ONC","LU1969619763.USD","BK1161","BK4526","BK1588","LU0588546209.SGD","BK1500","LU2328871848.SGD"],"gpt_icon":0},{"id":"2550694920","title":"百濟神州7月9日成交額為9172.04萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550694920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550694920?lang=zh_tw&edition=fundamental","pubTime":"2025-07-10 12:37","pubTimestamp":1752122269,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，百济神州成交额为9172.04万美元，成交额较昨日增加41.27%，当日成交量为36.11万股。百济神州于2025年7月9日涨4.59%，报255.69美元，该股过去5个交易日涨4.3%，年初至今涨38.43%，过去60日涨22.74%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710123750a6a0c521&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2550667221","title":"港股早評：三大指數低開 科技股多數下跌 寧德時代開漲2.6%再創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2550667221","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550667221?lang=zh_tw&edition=fundamental","pubTime":"2025-07-10 09:27","pubTimestamp":1752110862,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["JKS","MIUmain","02382","06978","METmain","KSTmain","161726","03750","09618","02833","01810","165316","03086","300750","688235","HMTD.SI","TTTN","01877","09999","BIDU","NTES","ONC","HSImain","MHImain","81024","159871","ALBmain","07226","02555","688180","89618","HHImain","06160","HSTECH","06683","HSI","XIACY","000819.SH","02097","HXXD.SI","JD","159992","HSCEI","BABA","MPNGY","03690","01024","YANG","399441"],"gpt_icon":0},{"id":"2550661203","title":"百奧賽圖與百濟神州達成抗體分子許可協議，加速創新藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2550661203","media":"美国商业资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550661203?lang=zh_tw&edition=fundamental","pubTime":"2025-07-10 00:00","pubTimestamp":1752076800,"startTime":"0","endTime":"0","summary":"-- 百奥赛图，一家创新技术驱动新药研发的国际性生物技术公司，今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款，百济神州将向百奥赛图支付首付款。关于百济神州百济神州是一家注册地位于瑞士的全球肿瘤治疗创新公司，专注于为全世界的癌症患者研发创新抗肿瘤药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK1583","LU0588546209.SGD","LU2328871848.SGD","ONC","02315","LU1969619763.USD","06160","BK1574","LU0307460666.USD","BK1161","BK1500","06978","BK1588"],"gpt_icon":0},{"id":"2550659831","title":"百濟神州美股漲逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550659831","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550659831?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 22:06","pubTimestamp":1752069960,"startTime":"0","endTime":"0","summary":"每经AI快讯，7月9日，百济神州美股涨逾3%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-09/doc-infewutf4583769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","688235","BK4526","BK0239","BK1500","LU0588546209.SGD","ONC","LU0307460666.USD","LU1969619763.USD","06160","BK4139","BK1583","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2550318655","title":"百濟神州美股漲逾3%一季度中國創新藥海外授權總額再創新高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550318655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550318655?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 22:04","pubTimestamp":1752069866,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0588546209.SGD","06978","BK0239","06160","LU2328871848.SGD","LU0307460666.USD","LU1969619763.USD","ONC","BK1574","BK4139","BK1500","BK1161","159992","BK1588","BK4526","688235","BK1583"],"gpt_icon":0},{"id":"2550655816","title":"【美股異動 | 百濟神州(ONC.US)漲逾3% 一季度中國創新藥海外授權總額再創新高】智通財經APP獲悉，週三，百濟神","url":"https://stock-news.laohu8.com/highlight/detail?id=2550655816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550655816?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 21:59","pubTimestamp":1752069554,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0405327494.USD","06978","LU1997245094.SGD","BK1588","LU1969619763.USD","BK4139","LU1064130708.USD","LU2148510915.USD","LU0588546209.SGD","LU1997245177.USD","BK1574","LU0405327148.USD","688235","LU1064131003.USD","03933","06160","BK0239","BK0012","BK1161","01276","LU1328615791.USD","LU2488822045.USD","BK0028","BK0060","BK1500","LU1655091616.SGD","BK1191","BK4526","LU0307460666.USD","BK0183","BK0196","LU2328871848.SGD","BK0188","159992","BK1583","LU1997244956.HKD","LU2495084118.USD","600276","ONC"],"gpt_icon":0},{"id":"2550165585","title":"美股異動 | 百濟神州(ONC.US)漲逾3% 一季度中國創新藥海外授權總額再創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2550165585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550165585?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 21:59","pubTimestamp":1752069554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百济神州涨逾3%，报252.97美元。尤其，中国创新药License-out交易额激增，2024年海外授权首付款31.6亿美元，交易总额511亿美元，联邦制药、恒瑞医药等多笔大额授权刷新纪录，全球BD交易占比升至30%。2025年一季度，海外授权总额再创455亿美元纪录，并且已经接近2024年全年水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","ONC","BK1161","06978","688235","LU2328871848.SGD","BK1588","LU1969619763.USD","BK4139","BK1500","159992","BK1583","BK4526","LU0588546209.SGD","LU0307460666.USD","06160","BK1574"],"gpt_icon":0},{"id":"2550504187","title":"百濟神州7月8日成交額為6492.56萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550504187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550504187?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 12:35","pubTimestamp":1752035720,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日，百济神州成交额为6492.56万美元，成交额较昨日减少16.17%，当日成交量为26.57万股。百济神州于2025年7月8日涨1.44%，报244.47美元，该股过去5个交易日涨0.99%，年初至今涨32.35%，过去60日涨18.49%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-16","current":-81.419242,"percent":0.028269,"low":-89.808695,"twenty":-46.404952,"median":-39.24538,"eighty":-23.17439,"high":-19.234246,"avg":-39.92818,"sd":18.073122,"marketCap":31946142462},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-16","current":-81.419242,"twenty":-46.404952,"median":-39.24538,"eighty":-23.17439,"marketCap":31946142462}],"updateTime":1752806579162}}}